Our observation that Rg5 combined with PD‐1 antibody can block PD‐L1/PD‐1 binding to significantly increase intratumoral CD8+ T‐cell populations and IFN‐γ release suggests an alternative option for therapeutic inhibition of CRC progression. This evidence concerns the gene IFNG and colorectal carcinoma.